FEMY earnings analysis
What we found in FEMY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Femasys reported Q2 2026 revenue of $331,827, down 18.9% year over year and approximately 21.9% sequentially, while diluted EPS improved to $(1.33) from $(3.18) in the prior-year quarter. A roughly $30.0 million financing and a 25.7% reduction in six-month R&D expense support liquidity and cost control, but ongoing losses, approximately negative $4 million of quarterly free cash flow, and weak revenue keep sentiment neutral. The 10-Q provided no quantitative revenue or EPS guidance and disclosed no material changes to previously reported risk factors as of August 14, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined year over year and sequentially
- Second-quarter revenue was $331,827, down 18.9% year over year and approximately 21.9% sequentially from $424,889 in Q1 2026.
- Per-share loss improved materially
- Diluted EPS improved to $(1.33) from $(3.18) in Q2 2025, a $1.85 per-share improvement.
- Six-month R&D expense decreased
- Six-month research and development expense declined 25.7% year over year, indicating lower clinical development spending.
- Approximately $30 million financing completed
- The company completed financing of approximately $30.0 million, improving near-term liquidity resources.
- Disclosure controls remained effective
- Management concluded that disclosure controls were effective at a reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Commercial traction remains weak
- Revenue of $331,827 was down 18.9% year over year, highlighting commercialization and demand-execution risk.
- Continued losses and cash burn
- Quarterly diluted EPS was $(1.33), and free cash flow was approximately negative $4 million in the latest reported quarter, indicating continued cash-burn risk.
- Clinical and regulatory risks persist
- The filing states there were no material changes to previously disclosed risk factors as of August 14, 2026; therefore, the principal clinical, regulatory and financing risks remain unchanged rather than resolved.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.33
- Segment
- Single reportable segment: revenue of $331,827
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing; outlook deferred to the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2026
- Femasys reported a notable rebound in Q1 2026 with revenue reaching $424,889, a 24.5% increase from the prior year. The company's net income turned positive at $846,100, reflecting a significant improvement over the…
- 10-K · March 31, 2026
- Femasys reported full-year 2025 revenue of $2,293,313 with sequential acceleration in H2 (Q3 $729,394; Q4 $813,387) driven by commercial expansion and regulatory milestones for FemBloc and FemaSeed. The company remains…
- 10-Q · August 8, 2025
- Femasys reported Q2 sales of $409,268 and GAAP net loss per share of $(0.16). Revenue increased versus the prior-year quarter ($221,484 in Q2 2024) and gross margin remained healthy at 61.4%, but the company generated…
- 10-K · March 27, 2025
- Femasys’ 10-K highlights material commercial and regulatory progress (CE mark for the FemBloc delivery system in March 2025; pivotal and peer‑reviewed clinical data for FemaSeed and FemBloc) while the company remains…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FEMY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever